Home - Melanoma Research Alliance

Full Sails Ahead: Immunotherapy Shows Continued Survival Benefit for Patients Facing Advanced Melanoma

After carefully following patients enrolled in Checkmate 067 over the last 6.5 years, he and the research team determined that 49% of patients treated with Opdivo + Yervoy were alive at 6.5 years and 77% of these patients remained treatment-free. This represents the longest reported median overall survival in a phase 3 melanoma clinical trial – ever.

Craig Finds Meaning in His Melanoma Diagnosis in the COVID-19 Era

“I believe there is a reason that I’m going through this. If I can help prevent someone else’s melanoma, or make their journey easier, or help advance research – that’d be worth it,” says Craig. “I feel honored to be part of the melanoma community. It’s a powerful community – and I feel obligated to do something in support of it.”

New Immunotherapy Drugs Targeting LAG-3 Show Great Promise

Researchers presented a series of highly encouraging clinical trial results at the recent American Society for Clinical Oncology (ASCO) annual meeting that suggest that new drugs targeting the protein LAG-3 – developed by BMS and Regeneron – may be an important addition to the current treatment arsenal.

UV Exposure & Risk of Cutaneous Melanoma in Skin of Color

In JAMA Dermatology, a team led by Adewole S. Adamson, MD, from The University of Texas at Austin, investigates whether there is an association, specifically in People of Color, between UV exposure and melanoma. MRA breaks down the research findings and evaluates how it should impact your sun safety practices.